Pneumococcal vaccine conjugate 13-valent - Walvax Biotechnology

Drug Profile

Pneumococcal vaccine conjugate 13-valent - Walvax Biotechnology

Alternative Names: 13-Valent pneumococcal conjugate vaccine - Walvax Biotechnology

Latest Information Update: 20 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Walvax Biotechnology
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Pneumococcal infections

Most Recent Events

  • 07 Apr 2016 Walvax Biotechnology plans a phase III trial for Pneumococcal infections (Prevention, In volunteers, In infants, In children) in China (Parenteral) (NCT02736240)
  • 31 Mar 2016 Clinical trials in Pneumococcal infections (Prevention, In volunteers) in China (Parenteral) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top